These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24106896)

  • 21. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
    Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
    Karthaus M; Tibor C; Lorusso V; Singh-Arora R; Filippov A; Rizzi G; Borroni ME; Rossi G; Grunberg SM
    Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
    Komatsu Y; Okita K; Yuki S; Furuhata T; Fukushima H; Masuko H; Kawamoto Y; Isobe H; Miyagishima T; Sasaki K; Nakamura M; Ohsaki Y; Nakajima J; Tateyama M; Eto K; Minami S; Yokoyama R; Iwanaga I; Shibuya H; Kudo M; Oba K; Takahashi Y
    Cancer Sci; 2015 Jul; 106(7):891-5. PubMed ID: 25872578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
    Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
    Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
    Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
    Einhorn LH; Brames MJ; Dreicer R; Nichols CR; Cullen MT; Bubalo J
    Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
    Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
    Ishido K; Higuchi K; Azuma M; Sasaki T; Tanabe S; Katada C; Yano T; Wada T; Koizumi W;
    Anticancer Drugs; 2016 Oct; 27(9):884-90. PubMed ID: 27254283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
    Damian S; Celio L; De Benedictis E; Mariani P; Agustoni F; Ricchini F; De Braud F
    Oncology; 2013; 84(6):371-7. PubMed ID: 23711719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
    Pacetti U; Veltri E; Fattoruso SI; Cardillo FD; Evangelista S; Cognetti F; Fabi A
    Anticancer Res; 2013 Apr; 33(4):1721-4. PubMed ID: 23564822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current status of the use of palonosetron.
    Navari R
    Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
    Lorusso V; Karthaus M; Aapro M
    Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
    Lajolo PP; de Camargo B; del Giglio A
    Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C; Gayle J; Balu S; Buchner D
    J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
    Okada Y; Oba K; Furukawa N; Kosaka Y; Okita K; Yuki S; Komatsu Y; Celio L; Aapro M
    Oncologist; 2019 Dec; 24(12):1593-1600. PubMed ID: 31217343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
    Vacirca J; Caruana D; Calcanes G; Mosier M; Boccia R; McBride A
    Future Oncol; 2018 Jun; 14(14):1387-1396. PubMed ID: 29421926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.